02142.HK
HBM Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 14.72
−2.52%Aug 27, 2026, 18:01 UTC
Harbour BioMed announced its interim results for the six months ended June 2026, with revenue of $122 million, up 20.9% year-on-year, and net profit of $64.88 million, down 9.5%.
Source:Aug 18, 2026, 09:05 UTC
China's National Medical Products Administration approved Harbour BioMed's IND application for HBM7004, a novel B7H4xCD3 bispecific antibody for advanced solid tumors, following prior FDA approval for a US Phase I trial.
Source:Aug 4, 2026, 15:45 UTC
AshakaCem Limited, a subsidiary of HBM Nigeria Plc, distributed fertilisers to farmers in its host communities of Ashaka and Maiganga, Gombe State, as part of its 2026 Agricultural Ecology Programme.
Source:Jul 24, 2026, 01:00 UTC
Harbour BioMed announced a positive profit alert for its 2026 interim results, marking its seventh consecutive profitable half-year.
Source: